News
Sermonix Poster Presentation at 2019 ASCO Annual Meeting Demonstrates Promise for Lasofoxifene in Treating ER+ Metastatic Breast Cancer Patients With ESR1 Mutations
Sermonix-sponsored University of Chicago preclinical investigation demonstrated: Lasofoxifene...
Lasofoxifene Shows Promise as Treatment for ER-Positive Metastatic Breast Cancer
CHICAGO—Findings suggest that lasofoxifene, in combination with CDK4/6 inhibitors like...
Sermonix Receives FDA Fast Track Designation for Investigational Drug Lasofoxifene
Designation allows for expedited development and review of lasofoxifene as a potential precision...
Sermonix to Present Poster on ‘Lasofoxifene as a Potential Treatment for ER+ Metastatic Breast Cancer’ at 2019 ASCO Annual Meeting
Biopharmaceutical company studied combination of lasofoxifene and CDK4/6 inhibitor palbociclib...
Sermonix Pharmaceuticals Adds Three New Members to Its Board of Directors
Richard U. DeSchutter, Michael A. Friedman and Stephen Rubino bring decades of diverse C-level...
Sermonix to Present at Boston Oncology Investor Conference on Potential for Lasofoxifene in Metastatic Breast Cancer Treatment
COLUMBUS, Ohio, March 11, 2019 (GLOBE NEWSWIRE) — Sermonix Pharmaceuticals LLC, a privately held...
Sermonix to Present Poster at ENDO 2019 on Lasofoxifene’s ‘Potent Anti-Tumor Activity’ in ESR1 Hormone-Resistant Breast Cancer
Biopharmaceutical company collaborated with Ben May Department for Cancer Research at University...
To sign up for future Sermonix press releases, please enter your information below.